Selective IDO1/TDO2 inhibitors that enhance or restore the immune response against several cancer entities (e.g., epacadostat, navoximod, BMS-986205, PF-06840003, and BAY 2416964) are being evaluated at different clinical phases394,496,497 (Table 4). The gene discussed is IDO1; the disease is cancer.